Express Healthcare

Vishat Diagnostic receives ICMR approval for its rapid testing antigen kit

0 307

This kit developed by Belgium’s Coris BioConcept is CE approved

Vishat Diagnostic has received the ICMR approval for its rapid testing antigen kit named as COVID-19 Ag Respi-Strip. The Mumbai-based firm plans to launch the antigen testing kit at an affordable cost of Rs 425. 

This international standard kit, developed by Belgium’s Coris BioConcept, is also CE approved and is used in several European countries and in North America. 

Pratik Chaitala, Managing Director, Vishat Diagnostics, said, “At a time when India is touching its peak in daily numbers of cases, it becomes critical to rapidly increase testing. With COVID-19 Ag Respi-Strip, we are bringing CE certified and ICMR approved kits at affordable prices, which is also our company’s driving force for all other product lines. We hope that it will help various state governments to fast pace the testing and isolation process.”

So far very few states like Delhi, Uttar Pradesh, and Maharashtra have given nod to rapid antigen testing kits. However, going forward it is anticipated that more and more states will adopt this strategy. 

Explaining the technical edge of this kit, Rohit Ramkumar, Technical Head, Vishat Diagnostics, said, “COVID-19 Ag Respi-Strip is a patient-centric product. Compared to other kits that need to collect two samples from one patient, our kit needs only one sample and thus has better patient compliance. Other antigen testing kits in the market need a nasal swab which is very inconvenient for the patient. Our kit works with both oral and nasal swabs and is easier on the patient.” COVID-19 Ag Respi-Strip can show results in a short span of fifteen minutes. If the test is found positive in COVID-19 Ag Respi-Strip there is no need for RT-PCR test. Hence saving cost, time and effort to detect COVID-19 patients.

- Advertisement -

Leave A Reply

Your email address will not be published.